Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | Director · President and CEO | May 15, 2026 | May 19, 2026 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,362,008 |
Last balance in matching sequence
After 2026-05-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-05-15 · Tax withholding · Disposed 128,497 · Balance 1,486,055 F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2022, April 3, 2023, February 23, 2024, and February 26, 2025. F2: Includes 1,362,008 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Row 2 · 2026-05-18 · Gift · Disposed 124,047 · Balance 1,362,008 F3: On May 18, 2026, the Reporting Person gifted 124,047 shares of Common Stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. F2: Includes 1,362,008 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 2,004,327 |
Reported balance
After 2026-05-18 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-05-18 · Gift · Acquired 124,047 · Balance 2,004,327 F3: On May 18, 2026, the Reporting Person gifted 124,047 shares of Common Stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. F4: Shares of Common Stock held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 17,728 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 17,728 F5: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2022, April 3, 2023, February 23, 2024, and February 26, 2025.
F2: Includes 1,362,008 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock.
F3: On May 18, 2026, the Reporting Person gifted 124,047 shares of Common Stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.
F4: Shares of Common Stock held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.
F5: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2026.
Vera Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20 | Direct | 17,084 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2020 Filed Apr 30, 2020 00:10 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 158,435 | $27.37 | $4,336,365.95 |
DisclosureSEC source: 0000939767-20-000059 · wf-form4_158820542239461.xml · nonDerivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,550 F4 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 126,565 shares of Common Stock on the net exercise of a stock option to purchase 285,000 shares of Common Stock. The Issuer withheld 158,435 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on April 27, 2020 of $27.37. Read SEC document |
| April 27, 2020 Filed Apr 30, 2020 00:10 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 285,000 | $1.70 | $484,500.00 |
DisclosureSEC source: 0000939767-20-000059 · wf-form4_158820542239461.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2020 Filed Apr 30, 2020 00:10 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 93,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000059 · wf-form4_158820542239461.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 600,761 F1 · kind: On April 27, 2020, the Reporting Person gifted 93,640 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended. F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. Read SEC document |
| April 27, 2020 Filed Apr 30, 2020 00:10 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 93,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000059 · wf-form4_158820542239461.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F1 · kind: On April 27, 2020, the Reporting Person gifted 93,640 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended. F2 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 23, 2020 Filed Apr 25, 2020 00:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 250,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000058 · wf-form4_158777524774901.xml · derivative · entry 6 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| April 23, 2020 Filed Apr 25, 2020 00:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 156,360 | $26.37 | $4,123,213.20 |
DisclosureSEC source: 0000939767-20-000058 · wf-form4_158777524774901.xml · nonDerivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,625 F4 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 93,640 shares of Common Stock on the net exercise of a stock option to purchase 250,000 shares of Common Stock. The Issuer withheld 156,360 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on April 23, 2020 of $26.37. Read SEC document |
| April 23, 2020 Filed Apr 25, 2020 00:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 250,000 | $5.51 | $1,377,500.00 |
DisclosureSEC source: 0000939767-20-000058 · wf-form4_158777524774901.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2020 Filed Apr 25, 2020 00:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 80,799 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000058 · wf-form4_158777524774901.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 507,121 F1 · kind: On April 23, 2020, the Reporting Person gifted 80,799 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. Read SEC document |
| April 23, 2020 Filed Apr 25, 2020 00:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 80,799 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000058 · wf-form4_158777524774901.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F1 · kind: On April 23, 2020, the Reporting Person gifted 80,799 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended F2 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 22, 2020 Filed Apr 23, 2020 01:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 87,079 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 8 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 426,322 F6 · kind: On April 22, 2020, the Reporting Person gifted 87,079 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended Read SEC document |
| April 22, 2020 Filed Apr 23, 2020 01:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 87,079 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 7 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,784 F6 · kind: On April 22, 2020, the Reporting Person gifted 87,079 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 01:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 220,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · derivative · entry 11 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 220,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Common Stock, became fully exercisable on September 18, 2017. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 01:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 139,201 | $24.56 | $3,418,776.56 |
DisclosureSEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 6 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,863 F5 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 80,799 shares of Common Stock on the net exercise of a stock option to purchase 220,000 shares of Common Stock. The Issuer withheld 139,201 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on April 21, 2020 of $24.56. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 01:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 220,000 | $5.51 | $1,212,200.00 |
DisclosureSEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 01:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 240,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · derivative · entry 10 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: On September 18, 2013, the Reporting Person was granted a performance-based stock option to purchase 480,000 shares of Common Stock under the Exelixis, Inc. 2011 Equity Incentive Plan. Vesting of the option is tied to performance goals set by the Compensation Committee ("Committee") as follows: (i) 50% of the option will vest if the Committee determines that top-line efficacy data received from the METEOR Phase 3 clinical trial of cabozantinib in metastatic renal cell carcinoma met its primary endpoint at a specified level, which the Committee determined had been achieved on July 20, 2015, resulting in the vesting of 50% of the option; and (ii) 50% of the option will vest if the Committee confirms the approval of cabozantinib by the U.S. Food and Drug Administration or European Medicines Agency for the treatment of metastatic castration-resistant prostate cancer, which the Committee determined could not be achieved on December 10, 2014, resulting in the forfeiture of 50% of the option. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 01:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 152,921 | $23.58 | $3,605,877.18 |
DisclosureSEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,064 F4 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 87,079 shares of Common Stock on the net exercise of a stock option to purchase 240,000 shares of Common Stock. The Issuer withheld 152,921 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on April 20, 2020 of $23.58. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 01:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 240,000 | $5.51 | $1,322,400.00 |
DisclosureSEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 09, 2020 Filed Apr 23, 2020 01:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 17,116 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 339,243 F1 · kind: On March 9, 2020, the Reporting Person gifted 17,116 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. Read SEC document |
| March 09, 2020 Filed Apr 23, 2020 01:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 17,116 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F1 · kind: On March 9, 2020, the Reporting Person gifted 17,116 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000043 · wf-form4_158354323258777.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,000 Underlying: Common Stock · 50,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 32,884 | $19.89 | $654,062.76 |
DisclosureSEC source: 0000939767-20-000043 · wf-form4_158354323258777.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,101 F2 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 17,116 shares of Common Stock on the net exercise of a stock option to purchase 50,000 shares of Common Stock. The Issuer withheld 32,884 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on March 4, 2020 of $19.89. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $5.51 | $275,500.00 |
DisclosureSEC source: 0000939767-20-000043 · wf-form4_158354323258777.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,985 shares of Exelixis, Inc. Common Stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 01:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000037 · wf-form4_158293829611013.xml · derivative · entry 6 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,000 Underlying: Common Stock · 25,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 01:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 500 | $19.60 | $9,800.00 |
DisclosureSEC source: 0000939767-20-000037 · wf-form4_158293829611013.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.52 to $19.71. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 01:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 24,500 | $18.90 | $463,050.00 |
DisclosureSEC source: 0000939767-20-000037 · wf-form4_158293829611013.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,485 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.49 to $19.47. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 01:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $5.51 | $137,750.00 |
DisclosureSEC source: 0000939767-20-000037 · wf-form4_158293829611013.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock · Derivative | 25,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000026 · wf-form4_158233339226188.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,000 Underlying: Common Stock · 25,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $21.75 | $543,750.00 |
DisclosureSEC source: 0000939767-20-000026 · wf-form4_158233339226188.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.23 to $22.05. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000026 · wf-form4_158233339226188.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 13, 2020 Filed Feb 15, 2020 01:48 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock · Derivative | 25,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000017 · wf-form4_158173128238093.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,000 Underlying: Common Stock · 25,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| February 13, 2020 Filed Feb 15, 2020 01:48 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $20.11 | $502,750.00 |
DisclosureSEC source: 0000939767-20-000017 · wf-form4_158173128238093.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.83 to $20.51. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 13, 2020 Filed Feb 15, 2020 01:48 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $5.51 | $137,750.00 |
DisclosureSEC source: 0000939767-20-000017 · wf-form4_158173128238093.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2020 Filed Feb 6, 2021 02:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 224,287 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000013 · wf-form4_161258002141849.xml · nonDerivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,166 F5 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F9 · date: On September 20, 2019, the Reporting Person was granted a PSU award the under 2017 Equity Incentive Plan covering 448,574 shares of common stock (such award, the "2019 Award," and such shares, the "Target Shares"). The 2019 Award generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement certain performance criteria as certified by Committee; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the 2019 Award provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the 2019 Award. F10 · shares: On February 3, 2021, the Committee determined the maximum performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 200% of the Target Shares subject to the 2019 Award. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and the remaining 25% of the Target Shares will vest on February 15, 2022, subject to the Reporting Person's continuous service through that date. F11 · balance_after: Includes 510,404 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of the restricted stock units. Read SEC document |
| January 29, 2020 Filed Feb 1, 2020 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock · Derivative | 25,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000013 · wf-form4_158051896775740.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,000 Underlying: Common Stock · 25,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| January 29, 2020 Filed Feb 1, 2020 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $17.87 | $446,750.00 |
DisclosureSEC source: 0000939767-20-000013 · wf-form4_158051896775740.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.77 to $18.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| January 29, 2020 Filed Feb 1, 2020 01:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $5.51 | $137,750.00 |
DisclosureSEC source: 0000939767-20-000013 · wf-form4_158051896775740.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 23, 2020 Filed Jan 25, 2020 01:19 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock · Derivative | 25,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000012 · wf-form4_157991515869661.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,000 Underlying: Common Stock · 25,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| January 23, 2020 Filed Jan 25, 2020 01:19 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $19.41 | $485,250.00 |
DisclosureSEC source: 0000939767-20-000012 · wf-form4_157991515869661.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.09 to $19.72. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| January 23, 2020 Filed Jan 25, 2020 01:19 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $5.51 | $137,750.00 |
DisclosureSEC source: 0000939767-20-000012 · wf-form4_157991515869661.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 16, 2020 Filed Jan 18, 2020 01:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock · Derivative | 25,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000009 · wf-form4_157931191763028.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,000 Underlying: Common Stock · 25,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| January 16, 2020 Filed Jan 18, 2020 01:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $20.33 | $508,250.00 |
DisclosureSEC source: 0000939767-20-000009 · wf-form4_157931191763028.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.09 to $20.70. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| January 16, 2020 Filed Jan 18, 2020 01:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $5.51 | $137,750.00 |
DisclosureSEC source: 0000939767-20-000009 · wf-form4_157931191763028.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 01:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock · Derivative | 25,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000004 · wf-form4_157862009508874.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,000 Underlying: Common Stock · 25,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 01:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $18.85 | $471,250.00 |
DisclosureSEC source: 0000939767-20-000004 · wf-form4_157862009508874.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.48 to $19.10. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 01:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $5.51 | $137,750.00 |
DisclosureSEC source: 0000939767-20-000004 · wf-form4_157862009508874.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 00:46 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock · Derivative | 25,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-20-000001 · wf-form4_157809878076118.xml · derivative · entry 6 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,000 Underlying: Common Stock · 25,000 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 00:46 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $17.49 | $437,250.00 |
DisclosureSEC source: 0000939767-20-000001 · wf-form4_157809878076118.xml · nonDerivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F4 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F5 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.28 to $17.66. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 5 to this Form 4. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 00:46 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $5.51 | $137,750.00 |
DisclosureSEC source: 0000939767-20-000001 · wf-form4_157809878076118.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2019 Filed Jan 4, 2020 00:46 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 128,129 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000001 · wf-form4_157809878076118.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 322,127 F1 · kind: On December 13, 2019, the Reporting Person gifted 128,129 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended. F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. Read SEC document |
| December 13, 2019 Filed Jan 4, 2020 00:46 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 128,129 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000001 · wf-form4_157809878076118.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 F1 · kind: On December 13, 2019, the Reporting Person gifted 128,129 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended. F2 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.